2021 American Transplant Congress
Low Immunogenic Donors Improved Survival of Kidney Transplants in African American Recipients
1University of Toledo, Toledo, OH, 2Bowling Green State University, Bowling Green, OH
*Purpose: Kidney transplants fail more often in African American (AA) than in Caucasian (CAU) recipients. We calculated the hydrophobic mismatch score (HMS) from polymorphic amino…2021 American Transplant Congress
hlaR,” a Simplified Interface for the HLA Matchmaker Tool
1Surgery, Emory University, Atlanta, GA, 2Pathology, Emory University, Atlanta, GA
*Purpose: Functional epitopes, or eplets, represent a set of amino acids within three angstroms of one another that may not be sequentially contiguous but are…2020 American Transplant Congress
Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy
University of Toledo, Toledo, OH
*Purpose: The induction therapy is currently used in the majority of kidney transplant recipients, regardless of their level of donor/recipient compatibility. We examined whether lower…2020 American Transplant Congress
A Simple HLA Class II Matching Strategy for the Prediction of De Novo Donor-Specific HLA Antibodies
*Purpose: In kidney transplantation, degree of HLA Class II mismatch (MM) between donor and recipient drives the risk to develop de novo DSA (dnDSA). New…2020 American Transplant Congress
HLA-DR/DQ Molecular Mismatch Dictates Early Risk of De Novo Donor-Specific Antibody Development and Offers a Personalized Approach to Immunosuppression Management in Kidney Transplantation
*Purpose: Clinicians have few tools to predict the risk of alloimmune injury in a patient undergoing renal transplantation, as traditional demographic or clinical variables lack…2020 American Transplant Congress
Identification of the dnDSA Inducing HLA Mismatches Across Multiple Renal Transplant Centers: A 3-Year Longitudinal Analysis of >11,000 HLA Mismatches in 2271 Patients
*Purpose: The presence of a mismatch (MM) between donor and recipient HLA does not always lead to the patient developing a de novo donor-specific anti-HLA…2020 American Transplant Congress
The Impact of a Positive Crossmatch on KAS Patients and Organs
1Medical Affairs, Hansa Biopharma, Camas, WA, 2Hansa Biopharma, Lund, Sweden, 3UNOS, Richmond, VA
*Purpose: Evaluate the potential effects of offer refusals due to positive crossmatch (+XM) on both patients and re-allocated organs with a focus on waitlist outcomes,…2020 American Transplant Congress
Interim Experience in a Phase 3 Prospective, Randomized, Multi-Center, Open-Label, Controlled Trial of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-Matched, Living Donor Kidney Transplants
*Purpose: The goals of tolerance in patients with kidney transplants (KTxp) are to eliminate the lifelong need for immunosuppressive drugs (IS) and to prevent graft…2020 American Transplant Congress
HLA Molecular Mismatch is an Independent Correlate of T-Cell Mediated Rejection and Potential Prognostic Biomarker in Renal Transplantation
*Purpose: HLA molecular mismatch alloimmune risk categorization has correlated with de novo donor-specific antibody (dnDSA) development, however, correlation with T-cell mediated rejection (TCMR) phenotypes is…2020 American Transplant Congress
Post- Transplant Recurrence of IgA Nephropathy: HLA as a Predictive Factor
*Purpose: Genomic studies have identified several HLA antigens to be associated with IgA Nephropathy in the native kidney. In contrast to the native kidney, there…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »